your badges 52W Range $34–$61 90% of range Analyst Rating HOLD 27 analysts Price Target $54 P/E 15.4 ROE 52.5% Net Profit Margin 39.8%

EXEL Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $58.39
Market Cap (MRQ) $14.53B
P/E (TTM) 15.4
EPS (TTM) $3.79
Revenue (TTM) $2.56B
ROE (TTM) 52.5%
52W Range $34–$61

EXEL Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

About Exelixis, Inc. - Common Stock Company overview from Wikipedia

05 · wikidata

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

History

Exelixis was founded in 1994; the scientific founders were Spyridon Artavanis–Tsakonas, at Yale at that time, and Corey Goodman and Gerry Rubin who were then at the University of California, Berkeley. George Scangos joined the company as CEO in 1996. The business plan was to use model organisms (fruit flies, nematodes, and zebrafish) and functional genomics to identify pathways and biological targets that could be exploited in the fields of agriculture and medicine. It eventually set up a subsidiary, Exelixis Plant Sciences, for the agricultural work.

By 2000, Exelixis had left the radical exploratory phase behind and became focused on drug discovery and had a chemical library of 4 million compounds. The company went public that year, after withdrawing its offering the week before; it raised $118 million in a down market.

In 2002, the company signed a broad alliance with GSK to discover new drugs in the fields of cancer, inflammatory diseases, and vascular conditions; GSK paid it $30 million in cash, bought $14 million in stock at twice the market rate, and committed to providing Exelixis with $90 million in research funding; it also offered loan financing of up to $85 million. By 2002, the company had limited its internal efforts to cancer, and had settled its strategy on discovering and developing drugs that could inhibit targeted small sets of tyrosine kinases that are needed for cancer formation, growth, and metastasis. The sets of TKs had been identified by means of its prior functional genomics work. This approach was controversial at the time; most companies try to selectively target just one protein in their discovery efforts.

In 2006, Exelixis partnered with Daiichi Sankyo on compounds that targeted mineralocorticoid receptors; esaxerenone was part of this collaboration. In 2007, the company partnered its MEK inhibitor program with Genentech; cobimetinib (at that time XL-518) was part of this collaboration. Exelixis had filed an IND on XL-518 prior to the partnership, committed to funding and running the Phase I trial, and retained rights to co-market it in the US.

In 2008, the company partnered its lead cancer drug candidate, XL-184 (which would become called cabozantinib) and another cancer candidate, XL-281, with Bristol Myers Squibb; BMS returned the rights to XL-184 to Exelixis in 2010 and returned the rights to other drug candidate in 2011.

In 2010, Scangos departed as CEO to take over at Biogen and the company appointed Michael M. Morrissey as president and CEO; Morrissey had joined the company in 2000 as Vice President of Discovery Research. At that time the company had eight drugs in clinical trials. Exelixis' first drug approval came in 2012, when cabozantinib was approved for medullary thyroid cancer, an orphan indication. It was approved in Europe in 2014. Exelixis invested heavily in exploring cabozantinib in other cancers, betting the future of the company on the drug. In 2014 the drug failed a Phase III trial in prostate cancer, and the company laid off 70% of its employees. In 2015, Genentech and Exelixis won FDA approval for cobimetinib for certain forms of melanoma.

In March 2016, Exelixis licensed to Ipsen worldwide rights (outside the US, Canada, and Japan) to market cabozantinib. In April 2016, the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer and the same was approved in Europe in October of that year.

In December 2017, the FDA granted approval for the use of cabozantinib for first line treatment of kidney cancer and in 2018 approval for first-line treatment was approved in Europe.

Finance

Pricing

Cabometyx (cabozantinib)

In 2023, the Institute for Clinical and Economic Review (ICER) identified Cabometyx (cabozantinib) as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Cabometyx's wholesale acquisition cost rose by 7.5%, leading to an additional $86 million in costs to U.S. payers.

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

sectorHealthcare industryBiotechnology employees1,077 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$2.32B
2016-12-31 → 2026-01-02
EPS$2.78
2017-12-29 → 2026-01-02
Free Cash Flow$876M
2017-12-29 → 2026-01-02
Net margin39.8%
2017-12-29 → 2026-01-02
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend EXEL 5Y avg Peer Median Verdict
P/E (TTM) 15.45Y avg ≈25.2 ≈25.2 21.1 Undervalued
P/S (TTM) 5.75Y avg ≈4.1 ≈4.1 5.4 Fair value
P/B (MRQ) 7.95Y avg ≈3.5 ≈3.5 7.5 Fair value
Price / FCF (TTM) 11.35Y avg ≈17.0 ≈17.0 · ·
Price / Cash Flow (TTM) 11.45Y avg ≈15.5 ≈15.5 13.3 Fair value
Price / Tangible Book 7.15Y avg ≈3.6 ≈3.6 · ·
PEG Ratio ≈0.3 · · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 15.3%
Next Report Nov 02, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Jul 27, 2026 $0.82 $0.80 2.3%
March 31, 2026 May 11, 2026 $0.79 $0.72 10.1%
Dec. 31, 2025 $0.88 $0.82 7.0%
Sept. 30, 2025 $0.69 $0.63 9.3%
June 30, 2025 $0.65 $0.57 14.0%
March 31, 2025 $0.55 $0.37 49.0%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 16
Metric Trend 20252024202320222021202020192018201720162015
Revenue $2.32B$2.17B$1.83B$1.61B$1.43B$988M$968M$854M$452M$191M$37M
Cost of Revenue $84M$76M$73M$58M$53M$36M$33M$26M$15M$7M$4M
R&D Expense $825M$910M$1.04B$892M$694M$548M$337M$182M$112M$96M$96M
SG&A Expense $519M$492M$543M$460M$402M$293M$228M$206M$159M$116M$57M
Operating Expenses $1.45B$1.56B$1.66B$1.41B$1.15B$877M$598M$415M$287M$220M$159M
Operating Income $872M$605M$171M$201M$287M$110M$369M$439M$166M$-28M$-121M
Interest Expense ······$0$0$9M$33M$41M
Other Non-op $-198.0K$-133.0K$93.0K$-197.0K$-184.0K$912.0K$680.0K$397.0K$-4M$5M$-381.0K
Pretax Income ·····$131M$398M$452M$159M$-70M$-162M
Income Tax $159M$160M$50M$52M$63M$19M$77M$-238M$4M$0$55.0K
Net Income $783M$521M$208M$182M$231M$112M$321M$690M$154M$-70M$-162M
EPS (Basic) $2.88$1.80$0.65$0.57$0.73$0.36$1.06$2.32$0.52·$-0.77
EPS (Diluted) $2.78$1.76$0.65$0.56$0.72$0.35$1.02$2.21$0.49·$-0.77
Shares (Basic) 271,567,000290,030,000318,151,000321,526,000314,884,000308,271,000302,584,000297,892,000293,588,000·209,227,000
Shares (Diluted) 281,863,000296,132,000321,464,000324,556,000322,359,000318,001,000315,009,000312,803,000312,003,000·209,227,000
EBITDA $901M$633M$197M$222M$300M$119M$378M$444M$167M··
Balance Sheet 27
Metric Trend 20252024202320222021202020192018201720162015
Cash & Equivalents $482M$217M$263M$501M$647M$319M$267M$315M$183M$152M$142M
Short-term Investments $577M$894M$732M$807M$820M$887M$586M$379M$205M$268M·
Receivables $287M$265M$237M$215M$283M$161M$119M$163M$77M$40M·
Inventory $22M$22M$17M$33M$27M$21M$13M$10M$7M$3M·
Prepaid Expense $76M$68M$68M$62M$58M$57M$27M$31M$9M$5M·
Current Assets $1.44B$1.47B$1.32B$1.62B$1.83B$1.45B$1.01B$897M$485M$469M·
PP&E (Net) $99M$119M$129M$111M$104M$67M$49M$51M$26M$2M·
PP&E (Gross) $231M$220M$209M$171M$145M$102M$74M$68M$49M$27M·
Accum. Depreciation $132M$101M$80M$61M$41M$35M$26M$17M$23M$25M·
Goodwill $64M$64M$64M$64M$64M$64M$64M$64M$64M$64M·
Other Non-current Assets ····$131M$73M$53M$8M$12M$1M·
Total Assets $2.84B$2.95B$2.94B$3.07B$2.62B$2.14B$1.89B$1.42B$655M$596M·
Accounts Payable $30M$38M$34M$33M$24M$24M$12M$11M$10M$7M·
Short-term Debt ········$0$80M·
Current Liabilities $406M$404M$394M$324M$338M$205M$143M$105M$115M$269M·
Capital Leases $173M$191M$190M$190M$51M$49M$48M$12M$15M··
Other Non-current Liabilities $104M$109M$94M$69M$8M$721.0K$2M$1M$2M$541.0K·
Total Liabilities $683M$703M$678M$583M$406M$258M$200M$135M$370M$506M·
Long-term Debt ········$0$189M·
Total Debt ········$0··
Common Stock $262.0K$282.0K$303.0K$324.0K$319.0K$312.0K$305.0K$300.0K$296.0K$290.0K·
Paid-in Capital $2.23B$2.34B$2.44B$2.54B$2.43B$2.32B$2.24B$2.17B$2.11B$2.07B·
Retained Earnings $-77M$-99M$-173M$-34M$-217M$-448M$-559M$-880M$-1.83B$-1.98B·
AOCI $3M$-1M$-4M$-15M$-758.0K$4M$3M$-701.0K$-347.0K$-416.0K·
Stockholders' Equity $2.16B$2.24B$2.26B$2.49B$2.21B$1.88B$1.69B$1.29B$285M$89M$-141M
Liabilities + Equity $2.84B$2.95B$2.94B$3.07B$2.62B$2.14B$1.89B$1.42B$655M$596M·
Shares Outstanding 262,483,000281,732,000302,793,000323,951,000318,842,000311,627,000304,831,000299,876,000296,209,000289,923,798227,960,943
Cash Flow 17
Metric Trend 20252024202320222021202020192018201720162015
D&A $29M$29M$26M$21M$14M$9M$8M$5M$1M$1M$1M
Stock-based Comp $113M$94M$106M$108M$120M$105M$57M$41M$24M$23M$22M
Deferred Tax $126M$-59M$-133M$-60M$47M$15M$71M$-244M$0$0$0
Restructuring $21M$34M$0$0···$0$-32.0K$63M$1M
Other Non-cash $-167M$116M$127M$112M$-10M$-32M$70M$-76M$-14M··
Operating Cash Flow $884M$700M$333M$363M$401M$209M$527M$416M$166M$206M$-141M
CapEx $8M$28M$40M$28M$54M$30M$13M$33M$21M$2M$447.0K
Investing Cash Flow $350M$-117M$-27M$-524M$-43M$-131M$-587M$-298M$37M$-216M$50M
Net Debt Issued ······$0$0$-186M··
Stock Issued ········$0$0$146M
Stock Repurchased $948M$652M$550M$0$0······
Net Stock Activity $-948M$-652M$-550M·····$0··
Financing Cash Flow $-970M$-629M$-546M$586.0K$-15M$-25M$13M$10M$-170M$20M$152M
Net Change in Cash $265M$-46M$-240M$-161M$343M$53M$-48M$128M$32M$10M$61M
Taxes Paid $155M$170M$186M$128M$13M$4M$8M$11M$538.0K··
Free Cash Flow $876M$672M$293M$335M$337M$179M$514M$382M$144M··
Levered FCF ······$514M$382M$136M··
Profitability 7
Metric Trend 20252024202320222021202020192018201720162015
Operating Margin 37.6%27.9%9.3%12.5%20.0%11.1%38.2%51.4%36.7%··
Net Margin 33.7%24.0%11.3%11.3%16.1%11.3%33.2%80.8%34.1%··
Pretax Margin ·····13.2%41.1%52.9%35.0%··
EBITDA Margin 38.8%29.2%10.7%13.8%20.9%12.1%39.0%52.0%36.9%··
ROA 27.0%17.7%6.9%6.4%9.7%5.6%19.4%66.4%24.7%··
ROE 37.3%23.1%9.0%7.3%10.7%6.0%19.5%62.6%82.4%··
ROIC ·····5.0%17.7%52.0%56.6%··
Liquidity & Solvency 4
Metric Trend 20252024202320222021202020192018201720162015
Current Ratio 3.63.63.35.05.47.17.18.54.2··
Quick Ratio 3.33.43.14.75.26.76.88.14.1··
Debt / Equity ········0.0··
Interest Coverage ········19.1··
Efficiency 3
Metric Trend 20252024202320222021202020192018201720162015
Asset Turnover 0.80.70.60.60.60.50.60.80.7··
Inventory Turnover 3.83.82.91.92.22.12.93.23.0··
Receivables Turnover 8.48.68.16.56.57.16.99.87.4··
Per Share 5
Metric Trend 20252024202320222021202020192018201720162015
Book Value / Share $8.23$7.97$7.48$7.68$6.93$6.03$5.53$4.29$0.96··
Revenue / Share $8.23$7.32$5.69$4.96$4.45$3.11$3.07$2.73$1.45··
Cash Flow / Share $3.14$2.36$1.04$1.12$1.24$0.66$1.67$1.33$0.53··
Cash / Share $1.84$0.77$0.87$1.55$2.03$1.02$0.87$1.05$0.62··
EPS (TTM) $2.78$1.76$0.65$0.56$0.72$0.35$1.02$2.21$0.49·$-0.77
Growth Rates 9
Metric Trend 20252024202320222021202020192018201720162015
Revenue YoY 7.0%18.5%13.6%12.3%45.3%······
Revenue CAGR 3Y 12.9%14.8%22.8%········
Revenue CAGR 5Y 18.6%··········
EPS YoY 58.0%170.8%16.1%-22.2%105.7%······
EPS CAGR 3Y 70.6%34.7%22.9%········
EPS CAGR 5Y 51.3%··········
Net Income YoY 50.1%150.9%14.0%-21.1%106.7%······
Net Income CAGR 3Y 62.5%31.1%22.9%········
Net Income CAGR 5Y 47.6%··········
Valuation (TTM) 14
Metric Trend 20252024202320222021202020192018201720162015
Revenue TTM $2.32B$2.17B$1.83B$1.61B$1.43B$988M$968M$854M$452M·$37M
Net Income TTM $783M$521M$208M$182M$231M$112M$321M$690M$154M·$-162M
Market Cap $11.44B$9.57B$7.26B$5.20B$5.83B$6.25B$5.19B$5.83B$9.00B··
Enterprise Value ········$8.62B··
P/E 15.719.336.928.625.457.316.78.862.0·-7.3
P/S 4.94.44.03.24.16.35.46.819.9··
P/B 5.34.33.22.12.63.33.14.531.6··
P / Tangible Book 5.54.43.32.12.73.4·····
P / Cash Flow 12.913.721.814.314.529.99.814.054.4··
P / FCF 13.114.324.815.517.335.010.115.262.3··
EV / EBITDA ········51.6··
EV / FCF ········59.6··
EV / Revenue ········19.0··
Earnings Yield 6.4%5.2%2.7%3.5%3.9%1.7%6.0%11.4%1.6%·-13.7%

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2026-01-022025-01-032023-12-292022-12-302021-12-31
Revenue $2.32B $2.17B $1.83B $1.61B $1.43B
Operating Margin % 37.6% 27.9% 9.3% 12.5% 20.0%
Net Income $783M $521M $208M $182M $231M
Diluted EPS $2.78 $1.76 $0.65 $0.56 $0.72

Institutional owners (13F) 806 filers · $14.5B total · As of Sept. 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 806
Value held $14.5B
New positions 129
Exited positions 62
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
129 (+13 vs prior Q) 62 (-11 vs prior Q) 252 (+12 vs prior Q) 282 (+16 vs prior Q) +15.7M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
BlackRock, Inc. $1,581,991,274 29,075,377 10.92% Shares
VANGUARD GROUP INC $1,117,246,380 25,490,449 7.71% Shares
FARALLON CAPITAL MANAGEMENT, L.L.C. $732,794,424 13,468,010 5.06% Shares
RENAISSANCE TECHNOLOGIES LLC $730,617,099 13,427,993 5.04% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $655,266,268 12,043,122 4.52% Shares
AQR CAPITAL MANAGEMENT LLC $598,600,120 11,023,943 4.13% Shares
VANGUARD CAPITAL MANAGEMENT LLC $595,843,747 10,950,997 4.11% Shares
STATE STREET CORP $542,471,563 9,970,071 3.74% Shares
FULLER & THALER ASSET MANAGEMENT, INC. $485,848,030 8,929,389 3.35% Shares
GEODE CAPITAL MANAGEMENT, LLC $416,318,915 7,650,316 2.87% Shares
D. E. Shaw & Co., Inc. $302,070,554 5,551,747 2.08% Shares
MORGAN STANLEY $245,916,111 4,519,684 1.70% Shares
Invesco Ltd. $244,610,874 4,495,697 1.69% Shares
DIMENSIONAL FUND ADVISORS LP $240,852,968 4,426,620 1.66% Shares
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $237,550,034 4,365,926 1.64% Shares
TWO SIGMA INVESTMENTS, LP $229,058,537 4,209,861 1.58% Shares
ASSETMARK, INC $186,834,364 3,433,824 1.29% Shares
Nuveen, LLC $178,300,700 3,276,984 1.23% Shares
UBS Group AG $172,364,895 3,167,890 1.19% Shares
Stephens Investment Management Group LLC $147,451,698 2,710,011 1.02% Shares
GOLDMAN SACHS GROUP INC $146,389,506 2,690,489 1.01% Shares
NORGES BANK $146,301,199 2,688,866 1.01% Shares
FIRST TRUST ADVISORS LP $138,383,701 2,543,353 0.96% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $123,065,409 2,261,816 0.85% Shares
BANK OF AMERICA CORP /DE/ $116,948,690 2,149,397 0.81% Shares
NORTHERN TRUST CORP $115,680,775 2,126,094 0.80% Shares
Caisse de depot et placement du Quebec $113,950,809 2,094,299 0.79% Shares
Allspring Global Investments Holdings, LLC $107,837,495 1,998,471 0.74% Shares
Bank of New York Mellon Corp $107,803,106 1,981,311 0.74% Shares
AMERICAN CENTURY COMPANIES INC $97,484,439 1,791,664 0.67% Shares
VANGUARD FIDUCIARY TRUST CO $86,563,209 1,590,943 0.60% Shares
Caligan Partners LP $84,512,985 1,553,262 0.58% Shares
JANE STREET GROUP, LLC $76,306,652 1,402,438 0.53% Shares
JPMORGAN CHASE & CO $71,082,192 1,298,907 0.49% Shares
MILLENNIUM MANAGEMENT LLC $66,309,793 1,218,706 0.46% Shares
SEI INVESTMENTS CO $63,480,220 1,166,715 0.44% Shares
LOS ANGELES CAPITAL MANAGEMENT LLC $63,086,055 1,159,457 0.44% Shares
FMR LLC $62,457,967 1,147,913 0.43% Shares
FRANKLIN RESOURCES INC $60,000,791 1,102,753 0.41% Shares
AMERIPRISE FINANCIAL INC $56,803,835 1,043,869 0.39% Shares
Robeco Institutional Asset Management B.V. $56,032,453 1,029,819 0.39% Shares
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $55,414,608 1,292,017 0.38% Shares
ENVESTNET ASSET MANAGEMENT INC $51,671,488 949,669 0.36% Shares
RAYMOND JAMES FINANCIAL INC $51,230,878 941,571 0.35% Shares
Gotham Asset Management, LLC $48,569,794 892,663 0.34% Shares
Swedbank AB $45,801,141 841,778 0.32% Shares
MARSHALL WACE, LLP $45,242,242 831,506 0.31% Shares
Retirement Systems of Alabama $44,107,739 810,655 0.30% Shares
BOOTHBAY FUND MANAGEMENT, LLC $43,750,809 804,095 0.30% Shares
Capital Impact Advisors, LLC $41,061,268 754,664 0.28% Shares

Show all 806 institutional owners →

Activists & 5%+ owners 4 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Roberts, Jr., Thomas G., Saito Edric C., Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. Aug. 14, 2026 5.60% Amendment · SEC
Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Fried, Richard B, Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Patel, Rajiv A., Roberts, Jr., Thomas G., Saito Edric C., Seybold, William, Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. ×8 filings Jan. 5, 2026 5.90% Amendment · SEC
Caligan Partners LP, David Johnson ×3 filings June 2, 2023 · Initial filing · SEC
Undisclosed reporting person Nov. 29, 2001 · Initial filing M&A / sale SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 43 insiders · 22 officers · 10 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Michael Morrissey President and CEO May 18, 2026 G 2,004,327 0 0 $0
Christopher J. Senner EVP and CFO May 18, 2026 S 952,317 0 3 $-4,556,048
Deborah Burke SVP & Chief Financial Officer Nov. 15, 2014 M 18,156 0 0 $0
Frank Karbe EVP and CFO Feb. 15, 2014 M 93,990 0 0 $0
Kristine M Ball Controller & Interim CFO Dec. 10, 2003 A 4,913 0 0 $0
Patrick J. Haley EVP, Commercial May 20, 2026 S 357,638 0 7 $-7,597,268
Brenda Hefti SVP and General Counsel May 18, 2026 S 106,762 0 2 $-1,154,264
Amy C. Peterson EVP Prod Dev & Med Aff & CMO May 16, 2025 M 465,393 0 0 $0
Jeffrey Hessekiel EVP & General Counsel May 15, 2025 S 693,396 0 0 $0
Vicki L Goodman EVP, Prod Dev & Med Aff &CMO April 3, 2023 A 307,654 0 0 $0
Peter Lamb EVP, Scientific Strategy & CSO Dec. 15, 2022 M 410,958 0 0 $0
Gisela Schwab Pres, Prod Dev & Med Aff & CMO July 26, 2021 M 689,078 0 0 $0
Pamela A Simonton EVP and General Counsel Nov. 15, 2013 M 17,139 0 0 $0
Lupe M Rivera EVP, Operations Aug. 15, 2011 M 19,219 0 0 $0
Frances K Heller EVP, Business Development May 15, 2011 M 17,125 0 0 $0
Ian D Malcolm VP, STRATEGIC MARKETING Dec. 8, 2006 A · 0 0 $0
Christoph Pereira VP, Legal Affairs & Secretary Dec. 8, 2006 A · 0 0 $0
Jeffrey Latts Executive VP, Development Dec. 8, 2006 A · 0 0 $0
Gregory Plowman Sr VP, CSO Dec. 13, 2004 A · 0 0 $0
Steven P James Sr VP, Commercial Ops Dec. 10, 2003 A · 0 0 $0
Jane M Green VP, Corp Communications Dec. 10, 2003 A · 0 0 $0
Geoffrey M Duyk Pres R&D & CSO Nov. 4, 2003 S 941,355 0 0 $0
Alan M Garber Director March 21, 2024 M 35,703 0 0 $0
Jacqueline Wright Director June 1, 2023 A 51,756 0 0 $0
Carl B Feldbaum Director Feb. 9, 2023 M 18,701 0 0 $0
Lance Willsey Director May 26, 2022 A 424,415 0 0 $0
Vincent T Marchesi Director May 26, 2022 A 93,989 0 0 $0
Charles Cohen Director July 6, 2021 M 261,375 0 0 $0
George A Scangos Director May 18, 2020 S 714,717 0 0 $0
FORMELA JEAN FRANCOIS Director Sept. 7, 2005 S 584,519 0 0 $0
Mary C Beckerle · Aug. 10, 2026 S 16,079 0 4 $-1,932,572
Sue Gail Eckhardt · June 1, 2026 S 16,079 0 2 $-660,828
Jack L Wyszomierski · June 1, 2026 S 284,384 0 2 $-4,580,661
Tomas J. Heyman · May 27, 2026 A 50,649 0 0 $0
Bob Oliver · May 27, 2026 A 29,487 0 2 $-1,325,340
Julie Smith · May 27, 2026 A 28,957 0 3 $-4,687,346
Maria C Freire · May 27, 2026 A 109,186 0 1 $-949,164
Stelios Papadopoulos · May 27, 2026 A 1,197,595 0 1 $-4,355,000
George Poste · May 27, 2026 A 127,199 0 1 $-2,742,600
Dana Aftab · May 26, 2026 S 594,741 0 4 $-7,701,255
Frank Mccormick · Dec. 6, 2013 A · 0 0 $0
Scott J. Garland · Sept. 18, 2013 A · 0 0 $0
Jason S Fisherman · Sept. 8, 2005 S 7,881 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 105 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
SAWG · ETF Series Solutions 3.56% 1,934 NS July 31, 2026 N-PORT
IDNA · iShares Trust 3.37% 150,179 SH Sept. 11, 2026 Daily
XMHQ · Invesco Exchange-Traded Fund Trust 3.31% 3,085,286 SH Oct. 2, 2026 Daily
PBE · Invesco Exchange-Traded Fund Trust 2.89% 206,883 SH Oct. 2, 2026 Daily
MCOW · Pacer Funds Trust 2.67% 535 NS July 31, 2026 N-PORT
PTH · Invesco Exchange-Traded Fund Trust 2.34% 116,260 SH Oct. 2, 2026 Daily
AZTD · Tidal Trust I 2.27% 16,241 NS July 31, 2026 N-PORT
GRPM · Invesco Exchange-Traded Fund Trust 2.07% 177,330 SH Oct. 2, 2026 Daily
LYLD · Cambria ETF Trust 1.84% 2,519 NS July 31, 2026 N-PORT
JSMD · Janus Detroit Street Trust 1.74% 344,438 NS July 31, 2026 N-PORT
BUL · Pacer Funds Trust 1.71% 42,248 NS July 31, 2026 N-PORT
ABOT · Abacus FCF ETF Trust 1.63% 1,243 NS July 31, 2026 N-PORT
JMID · Janus Detroit Street Trust 1.62% 7,222 NS July 31, 2026 N-PORT
RFG · Invesco Exchange-Traded Fund Trust 1.46% 84,215 SH Oct. 2, 2026 Daily
ABFL · Abacus FCF ETF Trust 1.38% 136,571 NS July 31, 2026 N-PORT
BBP · ETFis Series Trust I 1.37% 25,544 NS July 31, 2026 N-PORT
FXH · First Trust Exchange-Traded AlphaDE… 1.32% 261,689 NS July 31, 2026 N-PORT
VLLU · Harbor ETF Trust 1.18% 1,028 NS July 31, 2026 N-PORT
IBB · iShares Trust 1.04% 1,861,562 SH Sept. 11, 2026 Daily
COWG · Pacer Funds Trust 0.97% 406,060 NS July 31, 2026 N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust … 0.96% 17,520 SH Oct. 2, 2026 Daily
VAMO · Cambria ETF Trust 0.90% 18,388 NS July 31, 2026 N-PORT
CALF · Pacer Funds Trust 0.89% 614,023 NS July 31, 2026 N-PORT
SMDX · Tidal Trust III 0.88% 21,573 NS July 31, 2026 N-PORT
FLRG · FIDELITY COVINGTON TRUST 0.82% 45,034 NS July 31, 2026 N-PORT
LSEQ · Harbor ETF Trust 0.72% 2,087 NS July 31, 2026 N-PORT
IVOG · VANGUARD ADMIRAL FUNDS 0.72% 248,016 SH Aug. 19, 2026 Daily
PDP · Invesco Exchange-Traded Fund Trust 0.70% 178,291 SH Oct. 2, 2026 Daily
LABU · Direxion Shares ETF Trust 0.69% 64,176 NS July 31, 2026 N-PORT
HQGO · Lattice Strategies Trust 0.53% 4,942 NS July 31, 2026 N-PORT
LSVD · ADVISORS' INNER CIRCLE FUND 0.53% 64,827 NS July 31, 2026 N-PORT
PKW · Invesco Exchange-Traded Fund Trust 0.50% 144,182 SH Oct. 2, 2026 Daily
VFQY · VANGUARD WELLINGTON FUND 0.49% 42,746 SH Aug. 19, 2026 Daily
IQSM · New York Life Investments ETF Trust 0.47% 29,280 NS July 31, 2026 N-PORT
FNY · First Trust Exchange-Traded AlphaDE… 0.46% 50,608 NS July 31, 2026 N-PORT
QVMM · Invesco Exchange-Traded Fund Trust … 0.44% 31,352 SH Oct. 2, 2026 Daily
JPME · J.P. Morgan Exchange-Traded Fund Tr… 0.40% 35,114 NS July 31, 2026 N-PORT
JPUS · J.P. Morgan Exchange-Traded Fund Tr… 0.39% 33,972 NS July 31, 2026 N-PORT
ROUS · Lattice Strategies Trust 0.38% 50,612 NS July 31, 2026 N-PORT
PTMC · Pacer Funds Trust 0.37% 27,665 NS July 31, 2026 N-PORT
IVOO · VANGUARD ADMIRAL FUNDS 0.37% 406,142 SH Aug. 19, 2026 Daily
VBK · VANGUARD INDEX FUNDS 0.36% 3,162,797 SH Aug. 19, 2026 Daily
BKMC · BNY Mellon ETF Trust 0.31% 38,444 NS July 31, 2026 N-PORT
MIDU · Direxion Shares ETF Trust 0.29% 3,691 NS July 31, 2026 N-PORT
FSMD · FIDELITY COVINGTON TRUST 0.28% 131,971 NS July 31, 2026 N-PORT
TECB · iShares Trust 0.28% 24,022 SH Sept. 11, 2026 Daily
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0.26% 100,220 NS July 31, 2026 N-PORT
VFMF · VANGUARD WELLINGTON FUND 0.25% 31,728 SH Aug. 19, 2026 Daily
JMOM · J.P. Morgan Exchange-Traded Fund Tr… 0.24% 111,481 NS July 31, 2026 N-PORT
IYH · iShares Trust 0.23% 146,188 SH Sept. 11, 2026 Daily
ISCG · iShares Trust 0.22% 36,896 SH Sept. 11, 2026 Daily
FNX · First Trust Exchange-Traded AlphaDE… 0.22% 56,792 NS July 31, 2026 N-PORT
DFAS · Dimensional ETF Trust 0.21% 599,685 NS July 31, 2026 N-PORT
SMMD · iShares Trust 0.20% 132,873 SH Sept. 11, 2026 Daily
PWS · Pacer Funds Trust 0.19% 877 NS July 31, 2026 N-PORT
VHT · VANGUARD WORLD FUND 0.19% 706,287 SH Aug. 19, 2026 Daily
FHLC · FIDELITY COVINGTON TRUST 0.18% 111,648 NS July 31, 2026 N-PORT
ESML · iShares Trust 0.18% 85,358 SH Sept. 11, 2026 Daily
VB · VANGUARD INDEX FUNDS 0.16% 5,476,589 SH Aug. 19, 2026 Daily
VXF · VANGUARD INDEX FUNDS 0.15% 2,881,105 SH Aug. 19, 2026 Daily
FAD · First Trust Exchange-Traded AlphaDE… 0.14% 15,194 NS July 31, 2026 N-PORT
JQUA · J.P. Morgan Exchange-Traded Fund Tr… 0.13% 200,502 NS July 31, 2026 N-PORT
WSML · iShares Trust 0.13% 14,622 SH Sept. 11, 2026 Daily
VFVA · VANGUARD WELLINGTON FUND 0.11% 17,726 SH Aug. 19, 2026 Daily
IWP · iShares Trust 0.11% 358,092 SH Sept. 11, 2026 Daily
LRGF · iShares Trust 0.11% 68,576 SH Sept. 11, 2026 Daily
HDUS · Lattice Strategies Trust 0.11% 4,054 NS July 31, 2026 N-PORT
IWR · iShares Trust 0.11% 1,021,935 SH Sept. 11, 2026 Daily
IWS · iShares Trust 0.11% 278,528 SH Sept. 11, 2026 Daily
RWK · Invesco Exchange-Traded Fund Trust … 0.10% 21,854 SH Oct. 2, 2026 Daily
EQAL · Invesco Exchange-Traded Fund Trust … 0.10% 13,163 SH Oct. 2, 2026 Daily
OMFL · Invesco Exchange-Traded Self-Indexe… 0.08% 65,703 SH Oct. 2, 2026 Daily
DFUV · Dimensional ETF Trust 0.07% 214,466 NS July 31, 2026 N-PORT
DXUV · Dimensional ETF Trust 0.06% 5,961 NS July 31, 2026 N-PORT
DFAC · Dimensional ETF Trust 0.06% 512,586 NS July 31, 2026 N-PORT
DCOR · Dimensional ETF Trust 0.04% 28,149 NS July 31, 2026 N-PORT
IUSG · iShares Trust 0.04% 221,278 SH Sept. 11, 2026 Daily
IUS · Invesco Exchange-Traded Self-Indexe… 0.04% 6,205 SH Oct. 2, 2026 Daily
PRF · Invesco Exchange-Traded Fund Trust 0.03% 53,389 SH Oct. 2, 2026 Daily
VONV · VANGUARD SCOTTSDALE FUNDS 0.03% 112,032 SH Aug. 19, 2026 Daily
IWD · iShares Trust 0.03% 412,002 SH Sept. 11, 2026 Daily
TILT · FlexShares Trust 0.03% 11,534 NS July 31, 2026 N-PORT
DYNF · BlackRock ETF Trust 0.03% 190,630 SH Sept. 11, 2026 Daily
REVS · Columbia ETF Trust I 0.03% 1,649 NS July 31, 2026 N-PORT
DFAU · Dimensional ETF Trust 0.03% 58,894 NS July 31, 2026 N-PORT
IYY · iShares Trust 0.02% 10,758 SH Sept. 11, 2026 Daily
IWB · iShares Trust 0.02% 172,055 SH Sept. 11, 2026 Daily
VTI · VANGUARD INDEX FUNDS 0.02% 7,584,437 SH Aug. 19, 2026 Daily
VONE · VANGUARD SCOTTSDALE FUNDS 0.02% 41,043 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.02% 21,010 SH Aug. 19, 2026 Daily
ESGV · VANGUARD WORLD FUND 0.02% 56,278 SH Aug. 19, 2026 Daily
ITOT · iShares Trust 0.02% 328,550 SH Sept. 11, 2026 Daily
IWV · iShares Trust 0.02% 68,474 SH Sept. 11, 2026 Daily
DFUS · Dimensional ETF Trust 0.02% 76,305 NS July 31, 2026 N-PORT
RECS · Columbia ETF Trust I 0.02% 20,836 NS July 31, 2026 N-PORT
IWF · iShares Trust 0.01% 238,944 SH Sept. 11, 2026 Daily
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0.01% 214,636 SH Aug. 19, 2026 Daily
VONG · VANGUARD SCOTTSDALE FUNDS 0.01% 100,382 SH Aug. 19, 2026 Daily
IJH · iShares Trust · 8,819,629 SH Sept. 11, 2026 Daily
IJK · iShares Trust · 1,457,702 SH Sept. 11, 2026 Daily
XJH · iShares Trust · 34,337 SH Sept. 8, 2026 Daily
ISCB · iShares Trust · 10,294 SH Sept. 11, 2026 Daily
ISCV · iShares Trust · 24,871 SH Sept. 11, 2026 Daily
SMLF · iShares Trust · 251,598 SH Sept. 11, 2026 Daily
SMMV · iShares Trust · 21,241 SH Aug. 19, 2026 Daily

EXEL Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 27 analysts BUY
Median target $53.00 -9.2%
4 14.8% Strong Buy
8 29.6% Buy
14 51.9% Hold
1 3.7% Sell
0 0.0% Strong Sell

12-Month Price Target

15 analysts · 2026-10-01

Mean target $53.93 -7.6%

Now Current price $58.39
Low$41.00 Mean$53.93 High$66.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
EXEL $11.44B 15.7 7.0% 33.7% 37.3% ·
INSM $37.29B -27.1 66.7% -210.5% -128.4% ·
UTHR $21.27B 17.5 10.6% 41.9% 18.7% 87.9%
INCY $19.60B 15.4 21.2% 25.0% 27.6% ·
NBIX $14.20B 30.4 21.4% 16.7% 16.1% ·
SMMT $13.56B -12.1 · · -235.1% ·
BBIO $14.90B -20.2 126.3% -146.0% 41.2% ·
TWST $1.71B -21.6 20.3% -20.6% -17.0% ·
HALO $7.93B 26.3 37.5% 22.7% 166.1% ·
MDGL $13.30B -45.3 432.1% -30.1% -44.4% ·

Latest News Recent headlines mentioning this company

23
Prediction: This Stock Could Double By 2031 Nasdaq · 4 months, 2 weeks ago Exelixis, Inc. Reports Climb In Q1 Profit Nasdaq · 4 months, 4 weeks ago

Trading Signals Recent buy/sell signals with entry price and risk/reward ratio

25
BLUECHIP_DIP Stopped out Aug 7
risk 1 reward 1.67
entry $53.65 R:R 1.67
BLUECHIP_DIP Expired Mar 24
risk 1 reward 4.80
entry $41.37 R:R 4.80
BOUNCE_UP Expired Dec 9
risk 1 reward 2.00
entry $42.17 R:R 2.00
BOUNCE_UP Target hit Oct 20
risk 1 reward 1.50
entry $34.23 R:R 1.50

No open signal right now — no card is filled, and that's honest.

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 5, 2026